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Introduction. Survival outcomes in patients with unresectable colorectal cancer (CRC) liver metastasis treated by radiofrequency
ablation (RFA) combined with systemic chemotherapy and correlation with potential prognostic factors were investigated.
Material and Methods. A retrospective cohort study was conducted on 61 CRC patients with unresectable liver metastasis who
underwent liver tumor-directed percutaneous RFA combined with conventional systemic chemotherapy between October 2013
and September 2018. Survival analyses were conducted using the Kaplan-Meier method, and the log-rank test was used to
characterize differences in the median survival time and the 1-year, 3-year, and 5-year overall survival rates of subgroups to
identify prognostic factors. Results. Median overall survival and progression-free survival of all patients were 32 and 14 months,
respectively. The cumulative survival rates at 1-, 3-, and 5-years were 93.2%; 44.5%, and 38.2%, respectively. Univariate analysis
revealed that pre-RFA serum CEA levels, Eastern Cooperative Oncology Group (ECOG) status, number of liver lesions, the size
of the largest lesion, and the total lesion size were prognostic factors. However, multivariate analysis demonstrated that only the
number of liver lesions and the size of the largest lesion were independent prognostic factors for survival. Conclusion. RFA plus
systemic chemotherapy provides an encouraging survival outcome for patients with unresectable CRC liver metastasis.
Multivariate analysisdemonstrated that thenumberandsizeof livermetastatic lesions are independentprognostic factors for survival.
1. Introduction
Colorectal cancer (CRC) is the third most common cancer by
incidence and the second leading cause of cancer-related
deaths in both sexes [1]. The incidence of the disease in Viet-
nam has increased recently [2]. Synchronous liver metastasis
reportedly occurs in approximately 20–25% of CRC patients
at the time of initial diagnosis. Moreover, 20–30% of patients
progress to experience liver metastasis within the first three
years after CRC diagnosis. Liver metastasis is considered
the main cause of death in CRC patients [3, 4].
Systemic chemotherapy is the standard of care for CRC
patients with liver metastasis. However, liver metastatic
lesions typically respond poorly to chemotherapy alone; thus,
survival outcomes are suboptimal despite the recent intro-
duction of novel chemotherapeutic agents and targeted ther-
apies. Although liver resection is the most curative treatment
for liver metastasis, only about 20–25% of CRC patients with
liver metastasis are eligible for resection. Radiofrequency
ablation (RFA) is an alternative nonsurgical treatment for
CRC liver metastasis when the liver metastatic lesions are
not eligible for resection or because of comorbidities.
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However, data on the efficacy of RFA for the treatment of
CRC liver metastasis is still limited. Several clinical studies
demonstrated that RFA is an effective and safe treatment
for liver metastasis in CRC; however, local and distant recur-
rent rates remain high. The combination of RFA and sys-
temic chemotherapy has also been evaluated in some
clinical studies and resulted in promising outcomes for
CRC liver metastasis as demonstrated by progression-free
survival (PFS) and overall survival (OS). However, the treat-
ment outcome of treated patients is still heterogenous; we
are still in the lack of given factors that can be used for prog-
nosing the responses of patients [5–16]. Therefore, the aim
of our study was to evaluate survival outcomes and some
potential prognostic factors in patients with CRC liver
metastasis treated by using RFA combined with systemic
chemotherapy.
2. Materials and Methods
2.1. Patient Selection and Study Design. This retrospective
cohort study included 61 consecutive CRC patients with liver
metastasis who underwent percutaneous RFA combined
with systemic chemotherapy at 108 Military Central Hospi-
tal, Hanoi, Vietnam, between October 2013 and December
2018. The study was performed in accordance with the Dec-
laration of Helsinki (1975) and was approved by the Institu-
tional Review Board of 108 Military Central Hospital (O-
62720149). As this study was retrospective in nature, written
consent from the patients was not required.
The inclusion criteria for this study were as follows: (1)
colorectal adenocarcinoma confirmed by histopathology
after colorectal resection, (2) liver metastasis confirmed by
typical imaging diagnosis (intrahepatic hypo/isoattenuating
local lesions with peripheral enhancement in arterial phase
and washout in portal venous phase on contrast MDCT,
along with high FDG uptake on PET/CT: SUV > 3) [10–12]
or liver biopsy, (3) 1–5 liver lesions, (4) maximum size of
the largest liver lesion < 5 cm, (5) no clear evidence of extra-
hepatic spreads confirmed by chest/abdominal CT scans and
whole-body PET/CT scan, (6) aged 18–80, and (7) Eastern
Cooperative Oncology Group (ECOG) 0–1 without any
severe comorbidities, i.e., heart failure, renal failure, or respi-
ratory failure.
Patients were excluded if they had previous liver inter-
ventions or surgical liver resection, portal vein thrombosis,
presence of active gastrointestinal (GI) bleeding, and severe
coagulation abnormalities (prothrombin < 60%, platelet
count < 50G/l). Pregnant or feeding women were also
excluded.
All patients were discussed in a multidisciplinary tumor
board that included medical oncologists, liver surgeons,
radiologists, and hepatologists who performed RFA. The
number and the location of the liver lesions, the presence
or absence of extrahepatic metastasis, and comorbidities
were taken into consideration when determining treatment
approaches. Patients deemed to have resectable liver metas-
tasis with severe comorbidity were considered unsuitable
for surgery.
2.2. RFA Procedure and Chemotherapy Regimens. The Cool-
tip RF Ablation System E Series (USA) with multiple
probe approaches was used for the RFA technique and
performed by two hepatologists who had more than 5
years of experience in percutaneous local ablation for pri-
mary and secondary liver cancer. The intervention was
conducted percutaneously with ultrasound guidance, and
all patients were given local and intravenous anesthesia.
Each lesion was calculated to be ablated with at least a
5mm ablative margin. When lesions were located in difficult
locations (i.e., near gastrointestinal tract), an artificial-ascites
RFA procedure was used to avoid complications. Tumor
necrosis was evaluated by contrast-enhanced CT scan 2
weeks after intervention. A second additional RFA was con-
ducted in patients with incomplete tumor ablation. Systemic
chemotherapy was given to patients 2–4 weeks after RFA
intervention when all RFA-related adverse events had
resolved, and complete ablation of liver lesions was con-
firmed. FOLFOX-4 or FOLFIRI regimens were chosen for
each patient depending on which systemic treatment the
patient received for the primary cancer (FOLFOX-4 for first
line and FOLFIRI for second line chemotherapy).
Detail of chemo regimens [13]:
(i) FOLFOX-4: oxaliplatin 85mg/m2 intravenous (IV)
infusion over 2 hours day 1; folinic acid 200mg/m2
IV infusion over 2 hours day 1 + 2; fluorouracil
400mg/m2 IV bolus day 1 + 2 and fluorouracil 60
0mg/m2 IV infusion over 22 hours day 1 + 2. Total
of 12 cycles in every 2 weeks
(ii) FOLFIRI: irinotecan 180mg/m2 IV infusion over 90
minutes concurrently with folinic acid 400mg/m2 IV
infusion over 120 minutes, followed by fluorouracil
400mg/m2 IV bolus, then fluorouracil 2400mg/m2
IV infusion continuously over 46 hours. Total of 12
cycles in every 2 weeks
All patients were treated with pre-and postchemotherapy
antiemetics, including 5-HT3 blockers and dexamethasone.
Patient tolerance to chemotherapy was evaluated at the
time of the next cycle to adjust the dose of chemo drugs.
Follow-up images and serum CEA levels were obtained every
3 months after the first chemotherapy cycle to assess recur-
rence or progression. Patients with evidence of any recur-
rence or progression would receive further treatments or
just palliative care, after being reevaluated by a multidisci-
plinary tumor board.
2.3. Primary Endpoint. The primary endpoint of this study
was OS, defined as the date of RFA for liver metastases to
the date of death. Patients lost to follow-up were censored.
The second endpoint was progression-free survival (PFS),
defined as the date of RFA to the date of disease progression
or death.
2.4. Statistical Analysis. Baseline characteristics were
described as numbers (%) and mean with standard deviation.
Clinical variables included age, gender, ECOG, primary can-
cer, type of metastasis, number of liver metastatic lesions, size
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of the largest liver lesion, sum of lesion diameters, the type of
chemotherapy, and CEA levels. Chi-square or Fisher’s exact
tests were used to compare count data. The Mann–Whitney
U test was used to compare two continuous variables with
skewed distribution. Kaplan–Meier curves were constructed
to examine OS and PFS. We assessed potential predictors of
survival using univariate and multivariate Cox proportional
hazard regression analyses. The analysis was performed
using IBM SPSS Statistics for Windows, version 20.0 (SPSS
GmbH, Munich, Germany). Significant differences were
defined as p < 0:05.
3. Results
3.1. Baseline Clinical Characteristics. Sixty-one consecutive
CRC patients with liver metastasis were recruited for this
study. Baseline characteristics of study participants are listed
in Table 1. The median follow-up duration was 24 months,
the mean age was 56 years (range: 27–71), and there were
more males than females (n = 49, 80.3% vs. 12, 19.7%). All
patients were ECOG 0 or 1. Thirty-seven patients (60.7%)
were diagnosed with rectal cancer, and there were a total of
166 liver metastatic lesions treated with 78 RFA sessions. A
total of 17 patients were treated with an additional RFA
due to incomplete ablation after the first treatment, and they
all had complete liver lesion ablation after the second treat-
ment. Artificial ascites-assisted RFA was used in 40/61
patients (65.6%) who had liver metastatic lesions located at
the dome of the liver or near the GI tract.
All patients underwent twelve cycles of chemotherapy
(40 patients received FOLFOX-4 regimen and 21 others
were treated with FOLFIRI regimen). During follow-up,
16/61 (35.6%) of the patients had intrahepatic recurrence,
including 7 patients with local tumor progression and 9
patients with new lesions; 18/61 (40.0%) had extrahepatic
progression.
3.2. Treatment Outcomes. At the time of analysis, 24 patients
had died leaving 37 alive. In all cases, the cause of death was
disease progression. Kaplan Meier estimations for patient
survival demonstrated that (1) median (mean) overall sur-
vival time of all patients was 32 (37) months (95% confidence
interval (CI): 25–39) and (2) progression-free survival was 14
months (95% CI: 11–17). The cumulative survival rates at 1-,
3-, and 5-year follow-up were 93.2%; 44.5%, and 38.2%,
respectively. The median survival time and survival rates of
subgroups are presented in Table 2.
Univariate analysis revealed that the number of liver
lesions, the size of the largest lesion, the sum of lesion diam-
eter, and pre-RFA ECOG status were prognostic factors for
overall survival (Figure 1). Patients with 1–3 liver lesions
had an improved median OS, compared with patients who
had 4–5 liver tumors (41 months vs. 30 months, p = 0:008).
Patients in whom the size of the largest liver lesion was
<3 cm also had better median OS, compared with those in
whom the largest liver lesion was >3 cm (38 months vs. 30
months, p = 0:026). Significant differences in median OS
was also demonstrated based on ECOG status and levels of
serum CEA (p < 0:05). Notably, age, sex, primary cancer,
type of metastasis, and chemo regimen criteria did not corre-
late significantly with patient survival after treatment. A sub-
sequent multivariate analysis revealed that the number of
liver lesions (hazard ratio [HR] for 1–3 vs. 4–5, 2.91; confi-
dential interval, 1.1–7.4; p = 0:02) and the size of the largest
liver lesion (hazard ratio [HR] for ≤3 cm vs. 3–5 cm, 4.72;
confidential interval: 1.54–14.4; p = 0:01) were independent
predictors of OS (Table 3).
3.3. Complications. Post-RFA adverse events included right
upper quadrant pain (100%), fever (8/61–13.1%), vomiting
(4/61–6.6%), and elevated liver enzymes (100%); however,
all were mild and resolved within 2 weeks. Two patients
experienced pleural effusion after RFA, which resolved after
a few days; no other complications or deaths related to inter-
vention were reported.
4. Discussion
Although this was not a randomized study, the survival out-
comes of the CRC patients with liver metastasis reported here
Table 1: Baseline characteristics of study participants (n = 61).
Variables n = 61 (%)
Male 49 (80.3)














Number of liver metastatic tumors 166∗ (2:72 ± 1:34/patient)
1–3 41 (67.2)
4–5 20 (32.8)
Size of the largest liver lesion
≤3 cm 21 (34.4)
> 3 cm 40 (65.6)
Sum of lesion diameters †7:20 ± 3:95 cm
<5 cm 26 (42.6)
5–10 cm 21 (34.4)
>10 cm 14 (23.0)
Serum CEA
≤30 ng/mL 40 (65.6)
>30 ng/mL 21 (34.4)
ECOG: Eastern Cooperative Oncology Group. ∗Total number of liver
metastatic lesions. †Mean sum of tumor diameters in a patient.
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were encouraging considering historical controls treated with
systemic chemotherapy alone. It should be noted that even
with the recent approval of new chemo regimens, the survival
of patients with metastatic CRC has improved modestly to
roughly 18–24 months. Several previous studies of patients
with CRC liver metastasis have reported improved survival
(37–45 months) when systemic chemotherapy was combined
with local interventions, but outcomes were different in the
literature review. Shuangyan et al. retrospectively evaluated
the long-term survival of 109 CRC patients with liver metas-
tasis treated by RFA plus systemic chemotherapy in China
and demonstrated survival outcomes similar to those
reported here: (1) median survival of 39 months and (2) 1-
year, 3-year, and 5-year survival rates of 92.3%; 50.7%, and
41.6%, respectively [14]. Rues et al. reported the results of a
randomized phase II study (EORTC 40004) characterizing
RFA combined with systemic chemotherapy for unresectable
colorectal liver metastasis. Patients were randomized into
one of two treatment arms: (I) systemic chemotherapy alone
(FOLFOX/FOLFIRI plus bevacizumab) or (II) systemic che-
motherapy plus RFA for liver lesions. The median overall
survival of patients in arm I was 40.5 months, compared with
45.3 months for arm II combined treatment. The difference
was not significant (p = 0:22). However, RFA plus systemic
treatment resulted in significantly longer PFS (16.8 months
vs. 9.9 months, p = 0:025) [15]. Survival of patients in the
EORTC 40004 study, which was better than survival in the
study being described here, may be explained by the addition
of bevacizumab to systemic treatment and longer follow-up.
Bevacizumab is an expensive therapy and not fully covered
by government reimbursement; therefore, it is currently not
routinely used in clinical practices [16, 17]. Better survival
outcomes were also seen in a study of Solbiati et al. with a
median overall survival of 53 months, but the patient popu-
lation included only small, favorably located liver metastasis
(i.e., maximum diameter of any metastasis < 4 cm, each
>1 cm away from hepatic hilum or GI tract) with no extrahe-
patic disease, and a proportion of these patients was eligible
for resection [18]. Meanwhile, another prospective study by
Berber et al. in the United States, involving 135 patients with
CRC liver metastasis treated by laparoscopic RFA combined
with systemic chemotherapy, demonstrated a median overall
survival of only 28.9 months, shorter than that in our study.
Berber’s study recruited older patients (mean age 62 years
old), more patients with previous chemotherapy exposure
(108/135), and patients with extrahepatic disease, which
may explain the outcome [19]. Patient survival in the current
study was also higher than that in a study conducted by Gil-
lams et al. (median survival of 27 months; 1-, 3-, and 4-year
survival of 90%, 34%, and 22%, respectively). However, Gil-
lams and colleagues included patients across a broad spec-
trum of disease severity: (1) did not exclude those with
extrahepatic metastasis, (2) the number of liver lesions was
1–16, and (3) the diameters of lesions were 1–8 cm [20].






Male (n = 49) 35 (27–42) 0.155
Female (n = 12) 32 (27–39)
Age
<40 (n = 5) 40 (21–58) 0.66
40–60 (n = 35) 32 (25–38)
>60 (n = 13) 37 (31–42)
Number of liver lesions
1–3 (n = 41) 41 (35–48) 0.008
4–5 (n = 20) 24 (19–29)
Size of the largest liver lesion
≤3 cm (n = 21) 38 (35–51) 0.026
>3 cm (n = 40) 30 (15–44)
Sum of the diameter of liver lesions
<5 cm (n = 23) 43 (35–51) 0.011
5–10 cm (n = 24) 30 (25–36)
>10 cm (n = 14) 22 (16–27)
Primary cancer
Colon (n = 37) 40 (33–47) 0.263
Rectum (n = 24) 28 (23–33)
Type of metastasis
Synchronous (n = 24) 32 (28–35) 0.69
Metachronous (n = 37) 35 (29–50)
Chemo regimen
FOLFOX–4 (n = 40) 32 (23–46) 0.346
FOLFIRI (n = 21) 28 (23–33)
ECOG performance status
0 (n = 36) 42 (36–49) 0.003
I (n = 25) 24 (19–29)
Serum CEA
≤30 ng/mL (n = 40) 40 (33–46) 0.035
>30 ng/mL (n = 21) 25 (20–30)
ECOG: Eastern Cooperative Oncology Group; CEA: carcinoembryonic antigen.
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The effectiveness of RFA plus systemic chemotherapy in
improving survival varies; thus, an analysis of potential prog-
nostic factors of posttreatment survival is warranted. A mul-
tivariate analysis demonstrated that the number of liver
lesions and size of the largest lesion were both independent
predictors of patient survival. In the study by Berber et al.,
the size of the largest liver lesion and serum CEA levels was
significantly related to the overall survival of patients.
Patients with a serum CEA less than 200ng/ml had improved
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Figure 1: Survival rate subgroup analysis based on number of lesions in the liver (a), size of the largest liver lesion (b), ECOG status (c), pre-
RFA serum CEA status (d).
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200ng/ml (34 vs. 16 months; p = 0:01). The median survival
varied depending on the diameter of the largest liver lesion:
(1) 38 months (<3 cm), (2) 34 months (3–5 cm), and (3) 21
months (>5 cm) (p = 0:03), and the presence of extrahepatic
disease did not affect survival [19]. Shady et al. evaluated fac-
tors affecting outcomes of percutaneous RFA of CRC liver
metastasis in a retrospective single-center study with 10 years
of follow-up; using univariate analysis, the authors demon-
strated that the size of the largest liver lesion (greater or less
than 3 cm), serum CEA level (greater or lower 30ng/ml),
and presence or absence of extrahepatic diseases were inde-
pendent predictors for overall survival. However, multivari-
ate analysis revealed that only lesion size greater than 3 cm
and more than one site of extrahepatic diseases was indepen-
dent predictors of shorter overall survival [21]. In the analysis
reported here, no extrahepatic spreads or lymph node metas-
tases were present, an observation confirmed by chest/ab-
dominal CT scan or whole-body PET/CT.
Seifert and Morris investigated potential prognostic fac-
tors in 116 patients with CRC liver metastasis undergoing
cryotherapy and reported that low serum CEA levels
(<5ng/ml), small (≤3 cm) diameter of liver metastasis,
absence of untreated extrahepatic disease at laparotomy,
absence of nodal involvement at primary resection, complete
cryotherapy, synchronous development of liver metastasis,
and good or moderate differentiation of primary tumors were
independently associated with a favorable outcome [22]. The
liver-tumor burden impacts survival in this study, an obser-
vation that is corroborated by other studies. This can be
explained by the risk of microscopically incomplete ablation
in patients with higher liver tumor burden. We should note
that the liver tumor burden is also a very important risk fac-
tor for survival in patients with CRC liver metastasis after
resection [23, 24].
This study has some limitations. The small patient popu-
lation and the retrospective nature of the study are potential
drawbacks in that it might be insufficient to guide decisive
conclusions on the other potential prognostic factors tested.
However, the results of our study suggest that at least two
parameters (i.e., total lesion number and size of the largest
lesion) should be taken into account when considering RFA
plus systemic chemotherapy for CRC patients with liver
metastasis. The integration of these metastatic tumor charac-
teristics in predicting the long-term survival of patients with
CRC liver metastasis should also be addressed.
In conclusion, RFA plus systemic chemotherapy demon-
strates an encouraging survival outcome for patients with
unresectable CRC liver metastasis. The number of liver met-
astatic lesions ≤ 3 and size of the largest lesion ≤ 3 cm were








ECOG: Eastern Cooperative Oncology Group.
Data Availability
No data used to support the findings of the study.
Ethical Approval
This study was performed in accordance with the Declaration
of Helsinki (1975) and approved by the Institutional Review
Board of 108 Military Central Hospital (O-62720149).
Table 3: Multivariate analysis of independent prognostic factors for overall survival.
Variables
Multivariate analysis
HR (95% CI) p value
Age








Yes 2.08 (0.5–7.7) 0.26
Number of liver lesions
1–3 2.91 (1.1–7.4) 0.02
4–5
Size of the largest liver lesion




FOLFIRI 1.15 (0.36–3.66) 0.88
Serum CEA > 30 ng/mL No 1.73 (0.6–4.5) 0.25
Yes
CEA: carcinoembryonic antigen.
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